Press Releases

---

 FREDERICK, Md., Aug. 6, 2020 /PRNewswire/ -- A new exploratory study, conducted by NetNoggin®, highlights patient and caregiver reported change in lung function, expectations, and lexicon for patients who have been on TRIKAFTA.  The results of this exploratory analysis show that while TRIKAFTA met and even exceeded expectations for many patients, others were less satisfied by its effect. 

 FREDERICK, Md., July 28, 2020 /PRNewswire/ -- NetNoggin®, a premier market research agency that specializes in the pharmaceutical industry, has announced the release of its newest research report, NetNog: #genesis® Cystic Fibrosis V2.0 with updates due to TRIKAFTA. For the past nine months, NetNoggin® has been tracking this market disruption and reporting the impact TRIKAFTA is having on the cystic fibrosis market.   

 FREDERICK, Md., May 20, 2020 /PRNewswire/ -- An exploratory analysis, conducted by NetNoggin®, compares how the multiple myeloma and prostate cancer communities are experiencing and reacting to the COVID-19 pandemic. The analysis includes lexicon themes, attitudes, beliefs, volume of related conversations, and trending topics. In addition, NetNoggin® highlights areas in the patient journey where adjustments are made due to COVID-19. 

 FREDERICK, Md., May 1, 2020 /PRNewswire/ -- NetNoggin® released its newest NetNog: #track™ Alzheimer's (including MCI) report, which monitored first quarter 2020 brand performance, top influencers, and the top theme of COVID-19's impact on caregivers and patients with Alzheimer's.  NetNog: #track™ is a syndicated, quarterly report that tracks brands and monitors how the market is being influenced by caregivers, patients, HCPs, advocates, and organizations.  

FREDERICK, Md., April 8, 2020 /PRNewswire/ -- An exploratory analysis, conducted by NetNoggin®, compares three drastically different at-risk populations' reaction to the coronavirus crisis (including lexicon themes, volume of related conversations, and hot topics). The three therapeutic areas of focus in the analysis are: Alzheimer's patients (the elderly), Cystic fibrosis patients (the immunocompromised), and NAFLD patients (those with many comorbid conditions).

 FREDERICK, Md., March 25, 2020 /PRNewswire/ -- An exploratory study, conducted by NetNoggin®, revealed which biotech and pharmaceutical companies (developing NASH/NAFL drug candidates) are driving conversations online and how the community is reacting to their progress.   

The top five companies that drove the most conversation volume during the one year retrospective listening period were: Gilead Sciences, Genfit, Intercept Pharmaceuticals, Viking Therapeutics, and Pfizer.

 FREDERICK, Md., March 5, 2020 /PRNewswire/ -- NetNoggin® has released its newest product, NetNog: #track™ Alzheimer's Disease (including MCI). NetNog: #track™ is a syndicated, quarterly report that tracks brands and monitors how the market is being influenced by caregivers, HCPs, advocates, and organizations. NetNog: #track™ offers pharmaceutical companies an advantage when developing marketing strategies for new/established products by understanding how brands influence the market online and where a product may/does fit.   

 FREDERICK, Md., Dec. 12, 2019 /PRNewswire/ -- A new exploratory study, conducted by NetNoggin®, highlights the attitudes and beliefs of patients and caregivers regarding the approval of TRIKAFTA™ in the cystic fibrosis market.  NetNoggin® is also updating their syndicated report, NetNog: #genesis® Cystic Fibrosis, to reflect these changes in the market due to TRIKAFTA™.  NetNoggin® will continue to follow the patient journey disruption from January 1, 2020 to June 30, 2020. 

 FREDERICK, Md., Nov. 7, 2019 /PRNewswire/ -- An exploratory study, conducted by NetNoggin®, revealed healthcare providers (HCPs) in the nonalcoholic steatohepatitis (NASH), including nonalcoholic fatty liver (NAFL), market have multiple unmet needs within: research of NASH (including NAFL), pediatric nonalcoholic fatty liver disease (NAFLD), diagnosis and screening, treatment and management protocols, and education and awareness for patients and the general community.

 FREDERICK, Md., Oct. 2, 2019 /PRNewswire/ -- An exploratory study, conducted by NetNoggin®, revealed that among those impacted by Alzheimer's, hope of finding a cure is deflating due to recent Alzheimer's clinical trial failures in the past few years. 

 FREDERICK, Md., July 17, 2019 /PRNewswire/ -- NetNoggin® released detailed results from a netnographic-qualitative research study, which investigated levels of caregiving for patients with Alzheimer's disease and was presented at the Alzheimer's Association International Conference® (AAIC) 2019, held in Los Angeles, California, July 14 – 18.  

 FREDERICK, Md., July 16, 2019 /PRNewswire/ -- NetNoggin® released detailed results from a netnographic-qualitative research study, which investigated the utilization of technology in Alzheimer's disease (including mild cognitive impairment [MCI]), presented at the Alzheimer's Association International Conference® (AAIC) 2019 held in Los Angeles, California, July 14 - 18. 

FREDERICK, Md., May 21, 2019 /PRNewswire/ -- NetNoggin®, a premier market research agency that specializes in pharmaceutical marketing, has announced the release of its newest research, NetNog: #genesis® Nonalcoholic Steatohepatitis (NASH) (including Nonalcoholic Fatty Liver [NAFL]). 

 FREDERICK, Md., April 4, 2019 /PRNewswire/ -- NetNoggin® announced they will present additional findings from their Alzheimer's disease research report at the upcoming Alzheimer's Association International Conference (AAIC®). 

 FREDERICK, Md., Feb. 26, 2019 /PRNewswire/ -- In honor of Rare Disease Day on Thursday, NetNoggin®, a premier market research agency that specializes in pharmaceutical marketing, has announced the release of its newest offering, NetNog: #genesis® Cystic Fibrosis Patient and Caregiver Journeys. 

 FREDERICK, Md., Nov. 8, 2018 /PRNewswire/ -- NetNoggin®, a premier market research agency that specializes in pharmaceutical marketing, has announced the release of its newest research, NetNog: #genesis® Alzheimer's Disease (including Mild Cognitive Impairment [MCI]) 

 FREDERICK, Md., Oct. 19, 2018 /PRNewswire/ -- NetNoggin®, a premier market research agency that specializes in pharmaceutical marketing, has announced the release of its newest research, NetNog: #genesis® Cystic Fibrosis. 

 FREDERICK, Md., Oct. 17, 2018 /PRNewswire/ -- NetNoggin® has released its newest product, NetNog: #genesis®, offering pharmaceutical companies unmatched insights into their patients' and caregivers' real world lexicon, unmet needs, treatment flow process, and journey.